Interest of youth living with HIV in long-acting antiretrovirals

Ethel D. Weld, Md Sohel Rana, Ronald H. Dallas, Andres F. Camacho-Gonzalez, Patrick Ryscavage, Aditya H. Gaur, Rana Chakraborty, Susan Swindells, Charles Flexner, Allison L. Agwu

Research output: Contribution to journalArticle

Abstract

Objectives:This study's primary objective was to characterize attitudes to long-acting antiretrovirals (LAARV), among youth aged 13-24 years living with perinatally acquired HIV and nonperinatally acquired HIV. Secondary objectives included: assessing whether those with detectable HIV RNA PCR viral load had higher enthusiasm for LAARV compared to those with suppressed viral load, and examining characteristics associated with LAARV enthusiasm.Methods:A cross-sectional survey of 303 youth living with HIV (YHIV) followed at 4 pediatric/adolescent HIV clinics in the United States was performed to determine interest in LAARV, using a modified survey instrument previously used in adults. Interest in LAARV across groups was compared. Poisson regression with robust variance was used to determine the impact of various characteristics on interest in LAARV.Findings:Overall, 88% of YHIV reported probable or definite willingness to use LAARV. The enthusiasm level was similar between youth with perinatally acquired HIV and nonperinatally acquired HIV (P = 0.93). Youth with HIV viral load >1000 copies per milliliter had significantly higher interest than youth with suppressed viral load [prevalence ratio 1.12 (95% confidence interval: 1.03 to 1.20); P = 0.005]. Female youth participants who had had past experience with implantable contraceptive methods had a significantly higher interest in LAARV (100% vs. 85.5%; P = 0.002). Proportion of respondents endorsing definite willingness to use was significantly higher with decreased injection frequency compared with increased injection frequency.Interpretation:YHIV at 4 urban US pediatric/adolescent HIV clinics had high levels of enthusiasm for LAARV. LAARV should be given high priority as a potentially viable treatment option to improve clinical outcomes in YHIV.

Original languageEnglish (US)
Pages (from-to)190-197
Number of pages8
JournalJournal of Acquired Immune Deficiency Syndromes
Volume80
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

HIV
Viral Load
Pediatrics
Injections
Contraception
Cross-Sectional Studies
RNA
Confidence Intervals
Polymerase Chain Reaction

Keywords

  • HIV
  • HIV care continuum
  • adolescent
  • long-acting antiretroviral agents
  • patient acceptance of health care
  • treatment

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Weld, E. D., Rana, M. S., Dallas, R. H., Camacho-Gonzalez, A. F., Ryscavage, P., Gaur, A. H., ... Agwu, A. L. (2019). Interest of youth living with HIV in long-acting antiretrovirals. Journal of Acquired Immune Deficiency Syndromes, 80(2), 190-197. https://doi.org/10.1097/QAI.0000000000001896

Interest of youth living with HIV in long-acting antiretrovirals. / Weld, Ethel D.; Rana, Md Sohel; Dallas, Ronald H.; Camacho-Gonzalez, Andres F.; Ryscavage, Patrick; Gaur, Aditya H.; Chakraborty, Rana; Swindells, Susan; Flexner, Charles; Agwu, Allison L.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 80, No. 2, 01.02.2019, p. 190-197.

Research output: Contribution to journalArticle

Weld, ED, Rana, MS, Dallas, RH, Camacho-Gonzalez, AF, Ryscavage, P, Gaur, AH, Chakraborty, R, Swindells, S, Flexner, C & Agwu, AL 2019, 'Interest of youth living with HIV in long-acting antiretrovirals', Journal of Acquired Immune Deficiency Syndromes, vol. 80, no. 2, pp. 190-197. https://doi.org/10.1097/QAI.0000000000001896
Weld ED, Rana MS, Dallas RH, Camacho-Gonzalez AF, Ryscavage P, Gaur AH et al. Interest of youth living with HIV in long-acting antiretrovirals. Journal of Acquired Immune Deficiency Syndromes. 2019 Feb 1;80(2):190-197. https://doi.org/10.1097/QAI.0000000000001896
Weld, Ethel D. ; Rana, Md Sohel ; Dallas, Ronald H. ; Camacho-Gonzalez, Andres F. ; Ryscavage, Patrick ; Gaur, Aditya H. ; Chakraborty, Rana ; Swindells, Susan ; Flexner, Charles ; Agwu, Allison L. / Interest of youth living with HIV in long-acting antiretrovirals. In: Journal of Acquired Immune Deficiency Syndromes. 2019 ; Vol. 80, No. 2. pp. 190-197.
@article{9973bc22690447dcacf4bcfee1b74d3f,
title = "Interest of youth living with HIV in long-acting antiretrovirals",
abstract = "Objectives:This study's primary objective was to characterize attitudes to long-acting antiretrovirals (LAARV), among youth aged 13-24 years living with perinatally acquired HIV and nonperinatally acquired HIV. Secondary objectives included: assessing whether those with detectable HIV RNA PCR viral load had higher enthusiasm for LAARV compared to those with suppressed viral load, and examining characteristics associated with LAARV enthusiasm.Methods:A cross-sectional survey of 303 youth living with HIV (YHIV) followed at 4 pediatric/adolescent HIV clinics in the United States was performed to determine interest in LAARV, using a modified survey instrument previously used in adults. Interest in LAARV across groups was compared. Poisson regression with robust variance was used to determine the impact of various characteristics on interest in LAARV.Findings:Overall, 88{\%} of YHIV reported probable or definite willingness to use LAARV. The enthusiasm level was similar between youth with perinatally acquired HIV and nonperinatally acquired HIV (P = 0.93). Youth with HIV viral load >1000 copies per milliliter had significantly higher interest than youth with suppressed viral load [prevalence ratio 1.12 (95{\%} confidence interval: 1.03 to 1.20); P = 0.005]. Female youth participants who had had past experience with implantable contraceptive methods had a significantly higher interest in LAARV (100{\%} vs. 85.5{\%}; P = 0.002). Proportion of respondents endorsing definite willingness to use was significantly higher with decreased injection frequency compared with increased injection frequency.Interpretation:YHIV at 4 urban US pediatric/adolescent HIV clinics had high levels of enthusiasm for LAARV. LAARV should be given high priority as a potentially viable treatment option to improve clinical outcomes in YHIV.",
keywords = "HIV, HIV care continuum, adolescent, long-acting antiretroviral agents, patient acceptance of health care, treatment",
author = "Weld, {Ethel D.} and Rana, {Md Sohel} and Dallas, {Ronald H.} and Camacho-Gonzalez, {Andres F.} and Patrick Ryscavage and Gaur, {Aditya H.} and Rana Chakraborty and Susan Swindells and Charles Flexner and Agwu, {Allison L.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1097/QAI.0000000000001896",
language = "English (US)",
volume = "80",
pages = "190--197",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Interest of youth living with HIV in long-acting antiretrovirals

AU - Weld, Ethel D.

AU - Rana, Md Sohel

AU - Dallas, Ronald H.

AU - Camacho-Gonzalez, Andres F.

AU - Ryscavage, Patrick

AU - Gaur, Aditya H.

AU - Chakraborty, Rana

AU - Swindells, Susan

AU - Flexner, Charles

AU - Agwu, Allison L.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Objectives:This study's primary objective was to characterize attitudes to long-acting antiretrovirals (LAARV), among youth aged 13-24 years living with perinatally acquired HIV and nonperinatally acquired HIV. Secondary objectives included: assessing whether those with detectable HIV RNA PCR viral load had higher enthusiasm for LAARV compared to those with suppressed viral load, and examining characteristics associated with LAARV enthusiasm.Methods:A cross-sectional survey of 303 youth living with HIV (YHIV) followed at 4 pediatric/adolescent HIV clinics in the United States was performed to determine interest in LAARV, using a modified survey instrument previously used in adults. Interest in LAARV across groups was compared. Poisson regression with robust variance was used to determine the impact of various characteristics on interest in LAARV.Findings:Overall, 88% of YHIV reported probable or definite willingness to use LAARV. The enthusiasm level was similar between youth with perinatally acquired HIV and nonperinatally acquired HIV (P = 0.93). Youth with HIV viral load >1000 copies per milliliter had significantly higher interest than youth with suppressed viral load [prevalence ratio 1.12 (95% confidence interval: 1.03 to 1.20); P = 0.005]. Female youth participants who had had past experience with implantable contraceptive methods had a significantly higher interest in LAARV (100% vs. 85.5%; P = 0.002). Proportion of respondents endorsing definite willingness to use was significantly higher with decreased injection frequency compared with increased injection frequency.Interpretation:YHIV at 4 urban US pediatric/adolescent HIV clinics had high levels of enthusiasm for LAARV. LAARV should be given high priority as a potentially viable treatment option to improve clinical outcomes in YHIV.

AB - Objectives:This study's primary objective was to characterize attitudes to long-acting antiretrovirals (LAARV), among youth aged 13-24 years living with perinatally acquired HIV and nonperinatally acquired HIV. Secondary objectives included: assessing whether those with detectable HIV RNA PCR viral load had higher enthusiasm for LAARV compared to those with suppressed viral load, and examining characteristics associated with LAARV enthusiasm.Methods:A cross-sectional survey of 303 youth living with HIV (YHIV) followed at 4 pediatric/adolescent HIV clinics in the United States was performed to determine interest in LAARV, using a modified survey instrument previously used in adults. Interest in LAARV across groups was compared. Poisson regression with robust variance was used to determine the impact of various characteristics on interest in LAARV.Findings:Overall, 88% of YHIV reported probable or definite willingness to use LAARV. The enthusiasm level was similar between youth with perinatally acquired HIV and nonperinatally acquired HIV (P = 0.93). Youth with HIV viral load >1000 copies per milliliter had significantly higher interest than youth with suppressed viral load [prevalence ratio 1.12 (95% confidence interval: 1.03 to 1.20); P = 0.005]. Female youth participants who had had past experience with implantable contraceptive methods had a significantly higher interest in LAARV (100% vs. 85.5%; P = 0.002). Proportion of respondents endorsing definite willingness to use was significantly higher with decreased injection frequency compared with increased injection frequency.Interpretation:YHIV at 4 urban US pediatric/adolescent HIV clinics had high levels of enthusiasm for LAARV. LAARV should be given high priority as a potentially viable treatment option to improve clinical outcomes in YHIV.

KW - HIV

KW - HIV care continuum

KW - adolescent

KW - long-acting antiretroviral agents

KW - patient acceptance of health care

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85059879538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059879538&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000001896

DO - 10.1097/QAI.0000000000001896

M3 - Article

VL - 80

SP - 190

EP - 197

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 2

ER -